

REMARKS

By this amendment, claims 17-20 and 24-28 have been amended and claims 1-16 and 21-23 have been cancelled. The claims have been modified by deletion of subject matter covered in the parent cases.

Support for the changes to claim 17 may be found at page 36, line 31 – page 40, line 5 *inter alia*.

Support for the changes to claims 24 and 25 can be found on page 25, line 35 – page 26, line 29 *inter alia*.

Typographical and grammatical corrections have also been made throughout the specification.

No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with Applicants' Attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' Attorney.

Respectfully submitted,

Dated: March 12, 2004

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA